Continue to site >
Trending ETFs
You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

Name

As of 12/20/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Biotechnology Fund

RYCFX | Fund

$40.98

$104 M

0.00%

2.43%

Vitals

YTD Return

-4.3%

1 yr return

-2.6%

3 Yr Avg Return

-5.2%

5 Yr Avg Return

0.8%

Net Assets

$104 M

Holdings in Top 10

40.4%

52 WEEK LOW AND HIGH

$40.5
N/A
N/A

Expenses

OPERATING FEES

Expense Ratio 2.43%

SALES FEES

Front Load N/A

Deferred Load 1.00%

TRADING FEES

Turnover 65.00%

Redemption Fee N/A

Min Investment

Standard (Taxable)

$2,500

IRA

$1,000

Fund Classification

Fund Type

Open End Mutual Fund

Name

As of 12/20/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Biotechnology Fund

RYCFX | Fund

$40.98

$104 M

0.00%

2.43%

RYCFX - Profile

Distributions

  • YTD Total Return -4.3%
  • 3 Yr Annualized Total Return -5.2%
  • 5 Yr Annualized Total Return 0.8%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -1.58%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annual

Fund Details

  • Legal Name
    Biotechnology Fund
  • Fund Family Name
    Guggenheim
  • Inception Date
    Jun 09, 2003
  • Shares Outstanding
    N/A
  • Share Class
    C
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Michael Byrum

Fund Description

Under normal circumstances, the Fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. The Advisor employs a proprietary quantitative and qualitative methodology to identify Biotechnology Companies in which to invest. The methodology utilizes screens based on price, liquidity, and tradability. The securities are then weighted using a proprietary modified capitalization weighting methodology. The portfolio may be further adjusted to comply with regulatory investment limitations or as determined appropriate by the Advisor.The Fund may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. Biotechnology Companies may be engaged in a variety of activities, including the research, development, and manufacture of various biotechnological products, services, and processes; manufacture and/or distribute biotechnological and biomedical products, including devices and instruments; provide or benefit significantly from scientific and technological advances in biotechnology; or provide processes or services instead of, or in addition to, products. Biotechnology Companies also may include companies that are significantly involved in multiple industries, including the biotechnology industry. The Fund also may purchase American Depositary Receipts (“ADRs”) to gain exposure to foreign Biotechnology Companies and U.S. government securities.Investments in derivative instruments, such as futures and options, have the economic effect of creating financial leverage in the Fund’s portfolio because such investments may give rise to losses that exceed the amount the Fund has invested in those instruments. Financial leverage will magnify, sometimes significantly, the Fund’s exposure to any increase or decrease in prices associated with a particular reference asset resulting in increased volatility in the value of the Fund’s portfolio. The value of the Fund’s portfolio is likely to experience greater volatility over short-term periods. While such financial leverage has the potential to produce greater gains, it also may result in greater losses, which in some cases may cause the Fund to liquidate other portfolio investments at a loss to comply with limits on leverage imposed by the Investment Company Act of 1940, satisfy margin or collateral requirements, or meet redemption requests.In an effort to ensure that the Fund is fully invested on a day-to-day basis, the Fund may conduct any necessary trading activity at or just prior to the close of the U.S. financial markets. As of June 30, 2024, the Fund has significant exposure to the Health Care Sector, as that sector is defined by the Global Industry Classification Standard, a widely recognized industry classification methodology developed by MSCI, Inc. and Standard & Poor’s Financial Services LLC. Also, as of June 30, 2024, the Fund’s investments are concentrated (i.e., more than 25% of its assets) in securities issued by companies in the Biotechnology Industry, a separate industry within the Health Care Sector.
Read More

RYCFX - Performance

Return Ranking - Trailing

Period RYCFX Return Category Return Low Category Return High Rank in Category (%)
YTD -4.3% -27.8% 17.4% 89.94%
1 Yr -2.6% -26.1% 26.5% 86.16%
3 Yr -5.2%* -28.4% 23.9% 82.24%
5 Yr 0.8%* -11.4% 11.3% 86.58%
10 Yr 2.4%* -1.2% 12.6% 93.81%

* Annualized

Return Ranking - Calendar

Period RYCFX Return Category Return Low Category Return High Rank in Category (%)
2023 5.0% -12.6% 19.0% 23.90%
2022 -15.5% -53.9% 3.2% 74.34%
2021 -21.2% -39.6% 24.2% 87.50%
2020 10.1% -13.6% 178.2% 66.44%
2019 17.3% 3.8% 63.8% 75.19%

Total Return Ranking - Trailing

Period RYCFX Return Category Return Low Category Return High Rank in Category (%)
YTD -4.3% -27.8% 17.4% 89.94%
1 Yr -2.6% -26.1% 26.5% 86.16%
3 Yr -5.2%* -28.4% 23.9% 82.24%
5 Yr 0.8%* -11.4% 11.3% 86.58%
10 Yr 2.4%* -1.2% 12.6% 93.81%

* Annualized

Total Return Ranking - Calendar

Period RYCFX Return Category Return Low Category Return High Rank in Category (%)
2023 5.0% -12.6% 19.0% 40.88%
2022 -13.9% -53.9% 3.7% 78.29%
2021 0.8% -33.9% 26.0% 78.95%
2020 20.9% -0.7% 180.6% 57.72%
2019 23.8% 4.6% 63.8% 63.91%

NAV & Total Return History

RYCFX - Holdings

Concentration Analysis

RYCFX Category Low Category High RYCFX % Rank
Net Assets 104 M 6.43 M 45.7 B 76.73%
Number of Holdings 70 25 430 57.86%
Net Assets in Top 10 44.9 M 2.55 M 23.9 B 74.21%
Weighting of Top 10 40.42% 18.9% 78.1% 78.62%

Top 10 Holdings

  1. AbbVie, Inc. 8.74%
  2. Amgen, Inc. 6.01%
  3. Gilead Sciences, Inc. 4.67%
  4. Vertex Pharmaceuticals, Inc. 4.00%
  5. Regeneron Pharmaceuticals, Inc. 3.73%
  6. Corteva, Inc. 2.99%
  7. Alnylam Pharmaceuticals, Inc. 2.75%
  8. AstraZeneca plc 2.67%
  9. Biogen, Inc. 2.44%
  10. Moderna, Inc. 2.43%

Asset Allocation

Weighting Return Low Return High RYCFX % Rank
Stocks 		99.52% 89.92% 106.13% 18.87%
Cash 		2.01% 0.00% 33.01% 49.69%
Other 		0.66% -22.99% 23.24% 16.35%
Preferred Stocks 		0.00% 0.00% 7.86% 36.48%
Convertible Bonds 		0.00% 0.00% 0.37% 15.58%
Bonds 		0.00% 0.00% 12.39% 34.59%

Stock Sector Breakdown

Weighting Return Low Return High RYCFX % Rank
Healthcare 		96.38% 59.26% 100.00% 92.86%
Basic Materials 		3.62% 0.00% 7.16% 1.30%
Utilities 		0.00% 0.00% 0.00% 8.44%
Technology 		0.00% 0.00% 22.69% 15.58%
Real Estate 		0.00% 0.00% 5.89% 12.34%
Industrials 		0.00% 0.00% 7.02% 14.29%
Financial Services 		0.00% 0.00% 1.60% 32.47%
Energy 		0.00% 0.00% 0.00% 8.44%
Communication Services 		0.00% 0.00% 9.11% 11.69%
Consumer Defense 		0.00% 0.00% 25.73% 18.83%
Consumer Cyclical 		0.00% 0.00% 1.92% 14.29%

Stock Geographic Breakdown

Weighting Return Low Return High RYCFX % Rank
US 		99.52% 61.27% 104.41% 15.09%
Non US 		0.00% 0.00% 34.10% 66.67%

RYCFX - Expenses

Operational Fees

RYCFX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 2.43% 0.08% 4.48% 11.95%
Management Fee 0.85% 0.03% 1.25% 75.47%
12b-1 Fee 1.00% 0.00% 1.00% 80.52%
Administrative Fee 0.25% 0.03% 0.25% 72.97%

Sales Fees

RYCFX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load 1.00% 1.00% 1.00% 30.00%

Trading Fees

RYCFX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

RYCFX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 65.00% 0.00% 238.00% 79.26%

RYCFX - Distributions

Dividend Yield Analysis

RYCFX Category Low Category High RYCFX % Rank
Dividend Yield 0.00% 0.00% 6.24% 43.40%

Dividend Distribution Analysis

RYCFX Category Low Category High Category Mod
Dividend Distribution Frequency Annual Annual SemiAnnual Annual

Net Income Ratio Analysis

RYCFX Category Low Category High RYCFX % Rank
Net Income Ratio -1.58% -2.54% 1.85% 97.37%

Capital Gain Distribution Analysis

RYCFX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Distributions History

View More +

RYCFX - Fund Manager Analysis

Managers

Michael Byrum

Start Date

Tenure

Tenure Rank

Apr 01, 1998

24.18

24.2%

Michael P. Byrum, CFA, Senior Vice President—Mr. Byrum has been associated with the Security Investors since 1993. Mr. Byrum was the inaugural portfolio manager for many of the Rydex products, including the Rydex leveraged and inverse funds, sector fund lineup and alternative investment portfolios. Today, Mr. Byrum continues to play an instrumental role in product development and investment strategy at Guggenheim Investments and oversees the trading, research and portfolio management activities of the quantitative strategies team, which focuses on target beta, alternative and asset allocation strategies. He is the chairman of the Investment Strategy Committee and is a member of the Risk Management Committee and Credit Review Committee. Prior to joining the Security Investors， Mr. Byrum served in a brokerage capacity with Money Management Associates, the registered investment advisor to Rushmore Funds, Inc. He earned a B.S. in finance from the Miami University of Ohio. He also has earned the right to use the Chartered Financial Analyst® designation and is a member of the CFA Institute and the CFA Society of Washington.

Ryan Harder

Start Date

Tenure

Tenure Rank

Mar 14, 2008

14.22

14.2%

Ryan A. Harder, CFA, Managing Director and Portfolio Manager of Security Investors. Mr. Harder joined the Investment Manager in 2010.He also joined Rydex Investments in 2004 as an assistant portfolio manager, was promoted to portfolio manager in 2005 and has served in his current capacity since 2008. Prior to joining Rydex Investments, he served in various capacities with WestLB Asset Management, including as an assistant portfolio manager, and worked in risk management at CIBC World Markets.He holds a B.A. in Economics from Brock University in Ontario, Canada and a Master of Science in International Securities, Investment and Banking from the ICMA Centre at the University of Reading in the U.K. Harder holds the Chartered Financial Analyst designation.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.88 0.25

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.